Medical News

RSS

Drug-resistant HIV identified in New York

Health officials in New York say they have identified several patients who may have been infected with a rare strain of highly drug-resistant HIV, but whether the cases are related is uncertain at this stage.

30 Mar 2005

Primary health care providers should incorporate HIV testing into routine patient care for all sexually active individuals

Primary health care providers should incorporate human immunodeficiency virus (HIV) testing into routine patient care for all sexually active individuals, regardless of risk factors, say a group of physician/researchers at Emory University School of Medicine, Brown Medical School, and the Johns Hopkins School of Medicine.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

HIV patients who delay seeking care are much sicker when they begin care

Patients recently diagnosed with human immunodeficiency virus (HIV) are significantly more likely to seek medical treatment if they are followed even briefly by a case manager, according to findings of the national Antiretroviral Treatment Access Study (ARTAS).

30 Mar 2005

Urine actually helps a particular yeast stick to cells along the urinary tract

The finding might offer a new way to prevent or treat certain yeast and fungal infections, and the researchers' work also provides an unexpected new role for some proteins already known to help hungry yeast live longer.

30 Mar 2005

Solving sleep problems helps epileptic children

Sleeping woes may explain why children with epilepsy are often so hyperactive, say researchers with the University of Florida's Evelyn F. and William L. McKnight Brain Institute.

30 Mar 2005

Newly emerging illness, named staphylococcal purpura fulminans

Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus.

30 Mar 2005

A circadian rhythm gene discovered

A few rare people who consistently nod off early, then wake up wide-eyed much before dawn, can blame a newly-found mutant gene for their sleep troubles, Howard Hughes Medical Institute researchers announced today.

30 Mar 2005

Medication that both stimulates appetite and reduces metabolic rate

Scientists at Oregon Health & Science University, in collaboration with Neurocrine Biosciences Inc., have successfully tested a research medication that both stimulates appetite and reduces metabolic rate in preclinical trials.

30 Mar 2005

Finding opens new doors to determining susceptibility to antidepressant side effects

In a finding that opens new doors to determining susceptibility to antidepressant side effects, researchers at the UCLA Neuropsychiatric Institute report that changes in brain activity prior to treatment with antidepressants can flag patient vulnerability.

30 Mar 2005

First North American trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer

Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.

30 Mar 2005

Ranbaxy to appeal injunction against sales of Quinapril

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg).

30 Mar 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Hemodialysis causes antioxidant loss leading to long-term complications

An article published in Hemodialysis International discusses the role of oxidative stress (OS) in dialysis patients, an imbalance which can result in long-term health problems. Potential therapeutic options to restore balance in patients are also reviewed.

30 Mar 2005

Device may offer alternative for stroke patients

As the most common cause of adult disability in the United States, stroke leaves many survivors unable to perform tasks that were once part of their daily routine. Much of the time the disabilities are treatable, but the high cost of rehabilitation therapy leaves many patients to cope on their own.

30 Mar 2005

Pope John Paul II may need to be fed intravenously

The Pope apparently has had difficulty swallowing since a breathing tube was inserted late February.

30 Mar 2005

Avoiding risks of skin cancer from ultraviolet radiation (UVR)

Cancer Research UK has launched the SunSmart Campaign for 2005 and NRPB strongly supports the health promotion messages in the campaign.

30 Mar 2005

Protein Mnd2 protects chromosome bonds

The protein Mnd2 inhibits premature separation of chromosomes during the formation of gametes. The now published discovery of this regulatory function may help to understand the origin of some common congenital chromosome defects.

30 Mar 2005

High-rise homes have the highest levels of cockroach allergens

Roaches like to live high in the sky in places like Chicago, New York City and the Bronx, according to a recent study in the Journal of Allergy and Clinical Immunology. The study, conducted by an allergist affiliated with Children's Medical Center Dallas, found high-rise homes in Northeastern cities had the highest levels of cockroach allergens -- leading to a higher incidence of asthmatic episodes.

30 Mar 2005

$20 billion in cardiovascular drug revenues soon subject to patent expiration

More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next three to five years, according to a report by business intelligence firm Cutting Edge Information.

30 Mar 2005